A promising and effective platform for delivering hydrophilic depigmenting agents in the treatment of cutaneous hyperpigmentation: kojic acid nanostructured lipid carrier. Issue 1 (1st January 2021)

• Record Type: Journal Article
• Authors: Khezri, Khadijeh; Saeedi, Majid; Morteza-Semnani, Katayoun; Akbari, Jafar; Hedayatizadeh-Omran, Akbar
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 49:Issue 1(2021)
• Page Start: 38
• Page End: 47
• Publication Date: 2021-01-01
• Subjects: Melanin -- hydrophilic depigmenting agents -- kojic acid -- nanostructured lipid carrier -- skin permeation; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.1080/21691401.2020.1865993
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract: This study was aimed at preparing and characterising kojic acid nanostructured lipid carriers (KA-NLCs) for delivery to skin. KA-NLCs were prepared using high-speed homogenization followed by ultra-probe sonication method. KA-NLCs were optimized by glyceryl mono-stearate (GMS) and cholesterol (Chol) as solid lipid excipients, oleic acid (OA) as liquid lipid excipient, span 60 (SP 60) and Tween 20 (Tw 20) as co-emulsifiers. For optimized formulation (KA-NLC3 ), values of particle size, encapsulation efficiency, drug loading, polydispersity index (PDI) and zeta potential (ZP) were found to be 172.9 ± 7.1 nm, 76.4 ± 0.1%, 17.6 ± 1.3%, 0.3 ± 0.1 and −39.1 ± 2.7 mV, respectively. KA-NLC3 was stable at 4 °C and 25 for 3 months. TEM image confirmed these results. ATR-FTIR, DSC and PXRD results indicated suitable entrapment of KA in NLCs without any chemical interaction. The release profile of KA-NLC3 followed a sustained pattern. KA-NLC3 has potent tyrosinase inhibitory activity in comparison with pure KA. Nanoparticles showed a higher antioxidant activity than pure KA. The results of the ex vivo and in vitro percutaneous absorption showed that KA-NLC3 improved percutaneous delivery of KA. Concentrations below 250 μg/mL were determined as suitable concentrations for KA-NLC3 . It seems to be biocompatible formulation for the cosmetics aims.